Rosnilimab phase 2b trial shows promise in treating rheumatoid arthritis
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
